Skip to content
Baret News – Lifestyle
Author:
AbbVie Inc.
U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options
May 28, 2026
AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection
May 22, 2026
AbbVie to Present at the Bank of America Securities Healthcare Conference
May 6, 2026
Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month
April 30, 2026
AbbVie Reports First-Quarter 2026 Financial Results
April 29, 2026
AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn’s Disease
April 27, 2026
AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.
April 23, 2026
AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus
April 22, 2026
AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026
April 13, 2026
BOTOX® Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through “The Confidence Collective” for Fourth Year
April 8, 2026
1
2
3
Next Page
→